Newswire.com

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

Key Highlights

  • Record revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record
  • 2026 outlook reaffirmed: full-year revenue expected to surpass $90 million, up approximately 38%, the largest single-year revenue increase in the Company's history
  • Record fourth quarter expected: revenue of approximately $35.7 million or more, up approximately 81% from the fourth quarter of 2025
  • Multiple engines of growth: pharmaceutical contract manufacturing and distribution, proprietary brands and U.S. e-commerce all expected to contribute
  • U.S. e-commerce scaling rapidly: 8,940 active U.S. subscriptions as of October 19, 2026, up 42% in five days, with approximately $15 million in revenue and $10.5 million in gross profit expected in the fourth quarter
  • Record CMO pipeline: more than 32.7 million units at Cana Laboratories, up sixfold since mid-2024
  • Record distribution volumes: CosmoFarm serving more than 1,500 pharmacies, with revenue up approximately 4.3 times under Cosmos Health ownership
  • Global brand expansion: proprietary brands sold in more than 40 countries, with particular momentum in Europe and the Gulf
  • Diversified balance sheet: approximately $20 million in non-core assets, including real estate and digital assets, and total liabilities down 13.3% in the first half of 2026
  • Share repurchases: more than 5.1 million shares repurchased for approximately $1.1 million
  • R&D in weight management: advancing CCX0722, a hydrogel-based weight-management device with patent applications in four major markets
  • Path to 2029: <